[4-[1-(1-ethoxyethyl)-1H-pyrazol-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]methyl

1146629-76-6, also known as Baricitinib Intermediate 1, is an important chemical intermediate primarily used in the synthesis of Baricitinib, a Janus kinase (JAK) inhibitor drug for the treatment of conditions such as rheumatoid arthritis. This compound has the molecular formula C19H25N5O3 with a molecular weight of 371.43 and exists in solid form, characterized by its specific chemical structure and physical properties. In the pharmaceutical manufacturing field, 1146629-76-6 plays a significant role as a key step in the synthesis of Baricitinib, which is crucial for developing effective treatment plans. Additionally, due to its application in the synthesis process, 1146629-76-6 is also considered as Baricitinib Impurity 64 and Baricitinib Impurity 67, indicating its role in drug quality control and research.